NewsBite

Opinion

Sam Lovick

Caution over AstraZeneca comes at a cost

The comparative health costs say that restricting the use of the AstraZeneca vaccine is not worth the risk to herd immunity.

Sam LovickContributor

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Could we be about to see the federal government turn a silk purse into a sow’s ear? Their latest pronouncement on vaccination could do just that.

The government, with the assistance of the states and the acquiescence of a patient and compliant population, has managed to stem the worst effects of the global pandemic. They have done this by, in essence, closing the borders, injecting vast amounts of liquidity into the economy by subsidising jobs, and riding the resurgence of commodity prices. In large part, these have offset the disastrous effects of the pandemic on education and tourism.

Loading...
Sam Lovick is an independent economist and a former chief economist at CSL.

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Read More

Latest In Health & education

Fetching latest articles

Most Viewed In Policy

    Original URL: https://www.afr.com/policy/health-and-education/the-high-cost-of-vaccine-delays-20210411-p57iag